Stocktoria
BRISTOL MYERS SQUIBB CO BMY
BRISTOL MYERS SQUIBB CO (BMY) earns a Piotroski F-score of 7/9 (strong financial health). It pays a dividend yielding 4.30% (safety: stretched). FY2025 revenue was $48.2B at a 14.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.69 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-05 | Argus Research | Buy (up) |
| 2026-08-03 | Citigroup | Neutral (main) |
| 2026-07-31 | RBC Capital | Sector Perform (main) |
| 2026-07-31 | JP Morgan | Overweight (main) |
| 2026-07-31 | Cantor Fitzgerald | Neutral (main) |
| 2026-07-31 | Wells Fargo | Equal-Weight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
| ABT | ABBOTT LABORATORIES | 5/9 | 4.85 | 25.1 | +5.7% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| UPC | Universe Pharmaceuticals INC | 4/9 | 7.37 | — | -22.4% |
About BRISTOL MYERS SQUIBB CO
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
FAQ
Is BMY financially healthy?
BRISTOL MYERS SQUIBB CO's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak).
Does BMY pay a dividend, and is it safe?
Yes. BRISTOL MYERS SQUIBB CO pays a dividend yielding about 4.30% with a 71.5% payout ratio, rated “stretched” for safety.
How profitable is BMY?
In FY2025, BRISTOL MYERS SQUIBB CO had a net margin of 14.6% and a return on equity of 38.1%.
Is BMY overvalued or undervalued?
BRISTOL MYERS SQUIBB CO trades at about 18.4× trailing earnings — below its 10-year norm (10-year range 12.7×–102.6×, median 24.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for BMY?
The average Wall-Street price target for BRISTOL MYERS SQUIBB CO is $66.21, about 3.9% above the recent price, from 24 analysts (consensus: buy).
Is BMY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BRISTOL MYERS SQUIBB CO: a Piotroski F-score of 7/9, a P/E of about 16.7×, a dividend yield of 4.30%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.